Literature DB >> 3265563

Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets.

L Provinciali1, M A Laurenzi, L Vesprini, A R Giovagnoli, C Bartocci, M Montroni, P Bagnarelli, M Clementi, P E Varaldo.   

Abstract

Serum and CSF from 32 patients with idiopathic ALS, 30 age-matched controls and 30 MS patients were investigated regarding immunoglobulin concentration and virus-specific antibodies, the lymphocytes in the peripheral blood and lymphocyte subsets were also investigated. ALS patients' results were compared with findings in MS and controls. The ALS patients had significantly higher IgG concentration in serum than the controls, marked lymphopenia, reduction of CD2, CD8 and Leu 7 positive cells and increase of the CD4/CD8 ratio and of SIg-positive lymphocytes. Compared with the MS patients, the ALS patients showed similarity in T-subset distribution with a lower standard deviation. No HTLV-I and HIV antibodies were found in any group and no significant differences in antibody distribution to Toxoplasma G, herpes simplex, cytomegalovirus, measles and mumps viruses were evident. All ALS patients were investigated at an early disease stage, therefore, our findings seem to support the conclusion that the immune alterations are related to the mechanisms of the disease and not to complications of its evolution.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265563     DOI: 10.1111/j.1600-0404.1988.tb03686.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  Cytomegalovirus and multiple sclerosis risk.

Authors:  Julia Pakpoor; Jina Pakpoor; Giulio Disanto; Gavin Giovannoni; Sreeram V Ramagopalan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

Review 2.  Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications.

Authors:  Monika Haack; Norah Simpson; Navil Sethna; Satvinder Kaur; Janet Mullington
Journal:  Neuropsychopharmacology       Date:  2019-06-17       Impact factor: 7.853

3.  Mice deficient in the ALS2 gene exhibit lymphopenia and abnormal hematopietic function.

Authors:  Elizabeth A Erie; Hoon Shim; Aleah L Smith; Xian Lin; Keyvan Keyvanfar; Chengsong Xie; Jichun Chen; Huaibin Cai
Journal:  J Neuroimmunol       Date:  2006-12-06       Impact factor: 3.478

Review 4.  Alsin and the molecular pathways of amyotrophic lateral sclerosis.

Authors:  Jayanth Chandran; Jinhui Ding; Huaibin Cai
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

5.  Humoral factors in ALS patients during disease progression.

Authors:  Jared Ehrhart; Adam J Smith; Nicole Kuzmin-Nichols; Theresa A Zesiewicz; Israt Jahan; R Douglas Shytle; Seol-Hee Kim; Cyndy D Sanberg; Tuan H Vu; Clifton L Gooch; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Neuroinflammation       Date:  2015-06-28       Impact factor: 8.322

6.  Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis.

Authors:  Mengli Wang; Zhen Liu; Juan Du; Yanchun Yuan; Bin Jiao; Xuewei Zhang; Xuan Hou; Lu Shen; Jifeng Guo; Hong Jiang; Kun Xia; Jianguang Tang; Ruxu Zhang; Beisha Tang; Junling Wang
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

7.  Humoral immune activation in amyotrophic lateral sclerosis patients.

Authors:  Michael Rentzos; Maria Eleftheria Evangelopoulos; Eleni Sereti; Vassiliki Zouvelou; Styliani Marmara; Theodoros Alexakis; Ioannis Evdokimidis
Journal:  Neurol Int       Date:  2013-02-11

8.  Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.

Authors:  Rebecca Banerjee; R Lee Mosley; Ashley D Reynolds; Alok Dhar; Vernice Jackson-Lewis; Paul H Gordon; Serge Przedborski; Howard E Gendelman
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

9.  Melittin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model.

Authors:  Sun-Hwa Lee; Sun-Mi Choi; Eun Jin Yang
Journal:  Exp Neurobiol       Date:  2014-03-27       Impact factor: 3.261

Review 10.  Novel molecular biomarkers at the blood-brain barrier in ALS.

Authors:  Danijela Bataveljic; Milena Milosevic; Lidija Radenovic; Pavle Andjus
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.